Item request has been placed!

Item request cannot be made.

Processing Request

Skyrizi Overtakes Humira in U.S. Sales Numbers.

Item request has been placed!

Item request cannot be made.

Processing Request

Read Online Read More Add to Saved list

Author(s): Jeremias, Skylar
Source:
Formulary Watch. 11/8/2024, p1-1. 1p. 2 Color Photographs.

Additional Information
- Subject Terms:
  THERAPEUTIC use of monoclonal antibodies; ANKYLOSING spondylitis; PSORIASIS; JUVENILE idiopathic arthritis; PSORIATIC arthritis; CROHN'S disease; RHEUMATOID arthritis; SALES personnel; ULCERATIVE colitis; UNITED States. Food & Drug Administration; MONOCLONAL antibodies; BUSINESS; JANUS kinases; DRUG approval; ADALIMUMAB; NEUROTRANSMITTER uptake inhibitors; BIOSIMILARS
- Subject Terms:
  UNITED States
- Abstract:
  The article reports that Skyrizi has replaced Humira as AbbVie's sales driver largely because of companies encouraging product hopping to avoid competition, creating concerns for the sustainability of the adalimumab biosimilar market. According to AbbVie's report, the worldwide net revenues for the third quarter of 2024 reached 14,460 dollars for the first time. Also noted are the definition of product hopping and the launch of Amjevita (adalimumab-atto) by Amgen on the U.S. market in 2023.

Comments

No Comments.